Published in Science Immunology · View the paper (DOI)
Acalabrutinib improved oxygenation levels and decreased molecular markers of inflammation in most patients with severe COVID-19. The treatment showed promise in reducing the severity of the disease, particularly among those on mechanical ventilation.
Coverage from 2 institutions